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Abstract 
Background: During the last decade, Colombia presented a significant decrease in malaria clinical cases and associ‑
ated mortality. However, there is a lack of reliable information about the prevalence and characteristics of complicated 
malaria cases as well as its association with different Plasmodium species. A description of the epidemiological and 
clinical aspects of complicated malaria in Colombia is presented here.
Methods: A descriptive study was conducted using data collected between 2007 and 2013 by the Public Health 
Surveillance System (SIVIGILA). Demographic and clinical features were described. Frequency of complicated malaria 
cases, annual parasite index (API) and annual percent change (APC) for trend modelling by gender and age were also 
calculated.
Results: A total of 547,542 malaria cases were recorded by SIVIGILA during the study period, of which 2553 (0.47 %) 
corresponded to complicated cases with similar distribution by Plasmodium vivax and Plasmodium falciparum species. 
Mixed infections were found in 153 cases (6.0 %). Trend modelling of the API for complicated malaria for all parasite 
species showed a non‑significant increase throughout the years (APC 14.4 %; 95 % CI −4.3 to 36.6 %). Complicated 
malaria individuals were mostly males (62.2 %) and young adults (median age of 23 years). Notably, 72.4 % of the 
patients attended for malaria diagnosis >72 h after symptoms onset and 17 % reported malaria episodes in the 
last 30 days. All patients received anti‑malarial treatment, but only 40 % received the first‑line as recommended by 
the Colombian guidelines. Overall, hepatic and renal complications were the most common severe manifestations 
(63.6 %). Whereas hepatic and pulmonary complications were more common in P. vivax infections, renal and cerebral 
complications were significantly more frequent in patients with P. falciparum. In contrast with mono‑infected patients, 
severe anaemia and shock were more frequent in patients with mixed infection.
Conclusion: In contrast with the malaria‑decreasing trend over the last years, the complicated malaria trend showed 
a non‑significant annual increase. Therefore, in addition to existing national policies on early diagnosis and prompt 
anti‑malarial treatment, more efforts have to be committed addressing the delayed diagnosis and inadequate treat‑
ment found in this study. Improving malaria notification forms, medical assistance skills, and capacity should be 
prioritized.
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Background
Malaria continues to be an important public health 
problem in the developing world with 214 million clini-
cal cases and 438,000 deaths estimated worldwide in 
2015. Plasmodium falciparum is the predominant spe-
cies worldwide responsible for ~94  % of malaria cases 
[1]. Conversely, in the Americas region, where malaria 
transmission is typically defined as hypoendemic and 
unstable (annual parasite index, API  <  0.1 per 1000 per 
year) about 71 % of malaria cases are due to Plasmodium 
vivax [1]. In 2014, Colombia was the third most endemic 
country in Latin America (LA) and reported 17 % of the 
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total 390,000 malaria cases [1]. Nonetheless, the country 
has displayed a malaria decreasing trend in prevalence 
and mortality the last decade; from 121,629 cases and 87 
deaths in 2005 to 40,763 cases and 17 deaths in 2014 [1]. 
However, there is no reliable information about trends 
regarding complicated malaria cases.
Malaria exhibits a broad spectrum of clinical manifes-
tations, including asymptomatic infection, uncompli-
cated and complicated malaria. This spectrum depends 
on multiple parasite, host and environmental factors 
[2–4]. Whereas in areas of high malaria transmission, 
individuals continuously exposed to Plasmodium develop 
partial protection for severe symptoms at an early age [4]; 
under conditions of low and unstable malaria transmis-
sion, individuals of all age groups may present with acute 
or severe disease as a consequence of low levels of natu-
rally acquired immunity, although also subclinical infec-
tions are detected [4, 5].
In Colombia, a high frequency of uncomplicated P. 
vivax and P. falciparum malaria was reported recently 
[6], which appears to correlate with the relatively low 
malaria transmission and early diagnosis [7]. How-
ever, only a few studies have specifically focused on the 
description of complicated malaria cases in Colombia 
[8–14]. Before 2010, the criteria used for defining severe 
malaria in Colombia were the same established by the 
WHO for severe falciparum malaria [15], which were 
defined based on high transmission areas. In 2010, the 
Colombian Ministry of Health (MoH) adapted these 
criteria to the Colombian population, establishing more 
conservative parameters of complications to improve the 
detection and ensure a more effective treatment of these 
cases (Table 1).
In 2010, during a malaria outbreak in Colombia, 623 
(0.5 %) complicated malaria cases were diagnosed among 
the 117,108 total cases reported to the Public Health Sur-
veillance System (SIVIGILA) [16]. In this outbreak, the 
proportion of complicated malaria cases was similar for 
P. vivax and P. falciparum, with most patients (70.1  %) 
in the 15–64  years age group. In this and other studies 
[6, 17] hepatic and renal dysfunction were the most fre-
quently reported complications. However, some studies 
have reported either hyperparasitaemia [10], severe anae-
mia [9, 17], or severe thrombocytopaenia [8, 13] as main 
malaria complications in Colombia.
All complicated malaria studies conducted in Colom-
bia have been restricted to two of the most endemic areas 
in the country (Northwestern and Pacific regions), with 
many of them presenting gaps regarding epidemiologi-
cal and clinical characteristics of complicated malaria 
cases [6, 8–13, 17–20]. Indeed, associations between 
Plasmodium species and clinical profile have been 
hardly explored [6, 8, 11, 12]. The aim of this study was 
to describe the clinical and epidemiological characteris-
tics of complicated malaria in Colombia using national 
epidemiological records obtained by SIVIGILA from the 
whole country during the 2007–2013 period.
Methods
Study design and surveillance system
A descriptive study was conducted using data from the 
Colombian Public Health Surveillance System (SIVIG-
ILA) for the 2007–2013 period. Briefly, all malaria cases 
including complicated and deaths cases are reported 
to the SIVIGILA by the primary data generating units 
(PDGU) and the information units (IU). The PDGU are 
the health institutions or points-of-care (POC) from 
both the private and the public system, where micros-
copists and physicians report to SIVIGILA. The IU are 
mobile or permanent malaria-diagnosis posts, where a 
trained and certified “primary agent” usually from the 
community is responsible for malaria diagnosis, noti-
fication and treatment of uncomplicated malaria cases. 
Malaria infection is confirmed by microscopic exami-
nation of Giemsa-stained thick blood smear (TBS) or 
by a positive rapid diagnostic test [21]. Uncomplicated 
malaria cases are reported on a weekly basis while com-
plicated cases and deaths cases are reported on a daily 
basis [22].
Case definitions
Case definitions were used as established by the Colom-
bian MoH guidelines [21, 22]. A malaria case was defined 
by clinical malaria manifestations, i.e., history of fever 
and a positive TBS or RDT, regardless of the parasite 
species. Confirmed complicated malaria was defined as 
a malaria case with one or more of the clinical or labo-
ratory parameters as described in Table  1. Complica-
tions are reported as it is discriminated in the SIVIGILA 
malaria notification forms: hepatic, renal, pulmonary and 
cerebral complication.
Database mining and quality assurance
Databases were refined in agreement with SIVIGILA rec-
ommendations. Briefly, these recommendations included 
verification of data integrity, which means calculating the 
proportion of “empty data” and “no information data” for 
each study variable in the notification form. Only vari-
ables with integrity higher than 85  % were included in 
the study analyses. Integrity for demographic and epi-
demiological variables was higher than 99 %, whereas in 
some clinical and laboratory variables such as hyperem-
esis, shock, haemoglobin <5  g/dL and platelet counts 
<100,000 platelets/μL integrity was 88 %.
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Statistical analysis
Information was processed using Microsoft Excel spread-
sheets and analysed using GraphPad Prism version 6.0 
(GraphPad Software, San Diego, California, USA). The 
descriptive analysis included demographic and clini-
cal variables. Univariate analysis was performed for all 
variables. Frequencies, measures of central tendency and 
dispersion were calculated. Chi square test was used to 
compare proportion differences. Odds ratios (OR) and 
95 % confidence interval (95 % CI) were also calculated. A 
p value <0.05 was considered statistically significant.
The API for complicated malaria was calculated by 
relating the total number of complicated malaria cases 
with the population at risk multiplied by 100,000. Spe-
cific rates by 5-year age groups and gender were calcu-
lated and expressed as the number of cases per 100,000 
individuals per year. The Joinpoint Regression® software 
4.0.4 (Surveillance Research Program, National Cancer 
Institute, Bethesda, USA) was used to calculated compli-
cated malaria trends [23] adjusted by gender and API by 
5-year age groups from 2005 national census [24]. Briefly, 
this method allows to identify the time point (year in this 
case) where a significant change happens and to estimate 
the magnitude of this change through the annual per-
cent change (APC). A model using a maximum of three 
joinpoints was established to fits the simplest join-
point model that the data allow. Heteroscedasticity was 
assumed and Monte Carlo Permutation method and 
Bonferroni correction were used as tests of significance. 
Trends were interpreted as (i) rising when 95  % IC of 
APC was >0 and statistically significant; (ii) decreasing 
when 95 % CI of APC was <0 and statistically significant; 
(iii) stable when 95 % CI of APC was between −0.5 and 
0.5 and not statistically significant; (iv) non-significant 
when 95 % CI of APC was <−0.5 or >0.5 and not statisti-
cally significant. A p value <0.05 was considered statisti-
cally significant.
Results
Between 2007 and 2013, a total of 547,542 malaria cases 
were diagnosed and reported to SIVIGILA, with a notably 
decreasing trend over those years (Fig.  1a). While most 
of the cases corresponded to mono-infection caused by 
P. vivax (71.4 %) or P. falciparum (27.4 %), mixed malaria 
infection by both species were less frequent (1.2 %). Dur-
ing the same period, 2553 (0.47 %) complicated malaria 
Table 1 Malaria-related complications
DIC disseminated intravascular coagulation, SBP systolic blood pressure
a Includes only the changes based on previous evidence
b Currently classified as a warning sign for complicated malaria development
Criteria Defined before 2010 [22] Defined after 2010 [21]a
Cerebral malaria Impaired consciousness or coma (Blantyre score < 3 or 
Glasgow score < 9); unconsciousness with the possibility 
of waking up
Unchanged
Renal dysfunction Serum creatinine > 3.0 mg/dL and/or urine vol < 400 mL 
in 24 h (adults) or <12 mL/kg of body weight in 24 h 
(children)
Serum creatinine > 1.5 mg/dL
Hepatic dysfunction Serum bilirubin > 3 mg/dL and altered liver function tests Serum bilirubin > 1.5 mg/dL or aminotrans‑
ferases > 40 U/L
Respiratory distress Increased respiratory rate at admission, presence of abnor‑
mal lung sounds or pulmonary oedema (X‑rays)
Unchanged
Circulatory collapse or shock SBP < 70 mm Hg in adults or <50 mm Hg in children 
(3–5 years)
SBP < 80 mm Hg in adults
Hyperemesis >5 episodes in 24 h Not applicableb
Hyperpyrexia Axillary temperature >39.5 °C Not applicableb
Hypoglycaemia Blood glucose level < 40 mg/dL. Blood glucose level < 60 mg/dL
Severe anaemia Haemoglobin < 5 g/dL or haematocrit < 15 % Haemoglobin < 7 g/dL
DIC Abnormal bleeding in the presence of laboratory  
evidence of DIC
Unchanged
Acidaemia/acidosis and hyperlactemia Acidaemia/acidosis (clinical signs) Plasmatic bicarbonate < 15 mmol/L or base 
excess > −10; acidaemia pH <7.35; lactate 
acid > 5 mmol/L
Haemoglobinuria Macroscopic haemoglobinuria Macroscopic haemoglobinuria and positive urine 
dipstick
Hyperparasitaemia >100,000 asexual parasites/μL of P. falciparum or in mixed 
infection with P. vivax and schizontaemia
>50,000 asexual parasites/μL
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cases were reported. A total of 1274 (49.9  %) of them 
were caused by P. falciparum, 1126 (44.1  %) by P. vivax 
and 153 cases (6.0  %) corresponded to mixed malaria 
infections (P. falciparum plus P. vivax; Fig.  1b). How-
ever, the average proportion of complicated over total 
cases per parasite species was higher for mixed infection 
than for P. falciparum (2.6 vs 0.9 %, respectively) and P. 
vivax (0.3 %; Fig. 1c). Of the total complicated cases, 1139 
(44.6 %) were diagnosed between 2010 and 2011 (Fig. 1b). 
The highest numbers of cases were reported in the first 
semesters of 2010, 2011 and 2013 respectively, which cor-
responds with the average monthly highest incidence of 
malaria in Colombia, although transmission is reported 
throughout the year.
Most complicated malaria cases were recorded in the 
departments of Antioquia, Córdoba, Chocó, Nariño and 
Valle del Cauca (Fig.  2), all of them with endemic malaria 
transmission in several municipalities. Notably, four 
malaria-endemic municipalities in the Pacific Coast: Quibdó 
(Chocó), Buenaventura (Valle del Cauca), Istmina (Chocó), 
and Tumaco (Nariño) reported 21 % of the total complicated 
cases in the whole country. Moreover, cities without malaria 
transmission also reported complicated cases because 
patients from endemic municipalities are regularly referred 
to tertiary hospitals from other departments. Of those, Cali 
(Valle del Cauca) reported 7.1  % of the complicated cases, 
mainly referred from Buenaventura and Quibdó.
Population characteristics
Individuals with complicated malaria were mostly 
males (62.2  %; Table  2), with a median age of 23  years 
(range 0–94  years). The highest number of cases was 
reported in young adults between 20 and 29 years of age 
(n =  759, 29.7  %) and children younger than 5  years of 
age (n = 330, 12.9 %; Fig. 3). In children ≤15 years of age, 
mixed malaria was more frequent than single infections 
(p =  0.012; Table  2). Overall, patients presented late at 
health facilities for malaria diagnosis. Notably, 72.4 % of 
the patients attended for malaria diagnosis >72  h after 
symptoms onset (Table  2), a situation that was more 
frequent in the Pacific region (Additional file  1) and in 
patients with mixed malaria infection (p = 0.04).
Seventeen percent of the patients reported malaria epi-
sodes in the last 30 days, mainly those with mixed malaria 
infection. Only 4  % of cases referred blood transfusion 
history in the last month. About half of cases (47.5 %) had 
a history of travelling to a malaria-endemic region during 
the 15 days prior to diagnosis, 37 % of them to a distant 
region from their residency, mainly to the Pacific and 
Urabá regions; a situation that was more common in P. 
vivax-infected patients (p < 0.001). Although all patients 
received anti-malarial treatment according to the Colom-
bian guidelines [21], only 40 % of patients received first-
line treatment for complicated malaria whereas the 
remaining 60  % received either second or third line of 
treatment (Table  2). Unfortunately, complaints such as 
poor compliance of either dose or duration of treatment 
cannot be ruled out, as those are not registered in the 
malaria notification forms.
Fig. 1 Malaria cases in Colombia. The number of total malaria cases 
(a) and complicated malaria cases (b) reported monthly between 
2007 and 2013 are shown. Black dashed line (b), corresponds to 
the number of malaria‑related deaths per year. c Percentage of 
complicated malaria cases over total cases according to the parasite 
species
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Trend modelling of the API
The API for complicated malaria was 0.8 for 100,000 (1.01 
for male and 0.60 for female). Although some differences 
in the API were observed between P. falciparum and P. 
vivax infected patients (0.40 and 0.35 respectively) the 
APC for complicated malaria for both parasite species 
showed a non-significant annual increase in the whole 
population between 2007 and 2013 (14.4 %; 95 % CI −4.3 
to 36.6). Similar trends were observed for P. falciparum 
(15.0 %; 95 % CI −1.7 to 34.7) and P. vivax (14.6 %; 95 % 
CI −7.8 to 42.5; Fig.  4). Age-stratified analysis (Addi-
tional file  2) showed a significant rising trend between 
2007 and 2010 in the 0 to 4 years group (121.0 %; 95 % 
CI 8.4–350.5) and a stable trend between 2010 and 2013 
Fig. 2 Distribution of complicated malaria cases in Colombia. Percentage ranges of complicated malaria cases between 2007 and 2013 are shown 
for different regions in Colombia. The five departments reporting the highest number of cases are shown
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(−13.0 %; 95 % CI −39.0 to 24.1). A rising trend between 
2007 and 2013 was also observed for women, particularly 
in those infected by P. falciparum (Table 3).
Clinical findings
Some specific symptoms and signs were reported in com-
plicated patients in addition to those frequently observed 
Table 2 Characteristics of complicated malaria cases per parasite species
Most frequent and significant data are highlighted in italics
NS non significant
a p value using the Chi square test between parasite species
b During the current episode






Total (n = 2553) p valuea
n % n % n % n %
Gender
 Male 734 65.2 768 60.3 85 55.6 1587 62.2 0.010
 Female 392 34.8 506 39.7 68 44.4 966 37.8
Age
 ≤15 years old 268 23.8 366 28.8 47 30.7 681 26.7 0.012
 >15 years old 858 76.2 907 71.2 106 69.3 1871 73.3
Time between symptoms onset and diagnosis 0.044
 <24 h 149 13.2 129 10.1 13 8.5 291 11.4
 24–48 h 85 7.5 69 5.4 7 4.6 161 6.3
 48–72 h 110 9.8 129 10.1 13 8.5 252 9.9
 >72 h 781 69.4 947 74.3 120 78.4 1848 72.4
 No data 1 0.1 0 NA 0 NA 1 0.04
Travel to malaria‑endemic area in the last 15 days (yes) 625 55.5 536 42.1 52 34.0 1213 47.5 <0.001
Malaria episodes (last 30 days; yes) 219 19.4 187 14.7 35 22.9 441 17.3 0.001
Adequate anti‑malarial treatmentb 438 38.9 512 40.2 75 49.0 1025 40.1 ns
Blood transfusion (last 30 days; yes) 33 2.9 54 4.2 9 5.9 96 3.8 ns
Fig. 3 Parasite species distribution according to age. Percentage of complicated malaria cases with P. falciparum, P. vivax or mixed infections for 
5‑year age groups are shown. Black line corresponds to the percentage of total malaria cases (uncomplicated plus complicated) per group
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in acute malaria episodes (e.g., fever, headache, chills, 
and myalgias). Compared to patients with P. vivax mono-
infections, those with P. falciparum had a higher risk of 
confusion (OR 1.76, 95  % CI 1.20–2.62), clinical jaun-
dice (OR 1.60, 95 % CI 1.06–2.44), somnolence (OR 1.50, 
95 % CI 1.17–1.93), and hepatomegaly (OR 1.34, 95 % CI 
1.07–1.69). Interestingly, these manifestations were even 
more frequent in patients with mixed malaria infections 
(Table 4).
According to SIVIGILA classification, hepatic (33  %) 
and renal (31 %) complications were the most frequently 
presented regardless of parasite species. Renal (34.7 %) and 
cerebral complications (15.3  %) were significantly more 
common in patients with P. falciparum, while hepatic 
(37 %) and pulmonary complications (15.1 %) were more 
frequent in P. vivax cases (Table 5). Furthermore, a higher 
proportion of severe anaemia (10.9 %) and shock (3.3 %) 
was seen in patients with mixed malaria (Table 4).
Malaria‑related deaths
During 2007 and 2013, 116 (0.02  %) malaria-related 
deaths were reported (Fig.  1b). Those remained rela-
tively low and decreased during the study period, 
with a mean of 17 ±  5 deaths per year and a mean of 
2.2  ±  0.6 deaths per 10,000 total malaria cases. The 
malaria-related fatality rate (over all malaria cases) 
ranged between 0.02 and 0.03  %. Although a similar 
number of deaths was reported in mono-infections, the 
fatality rate per species was higher in those infected by 
P. falciparum than P. vivax (0.03 vs 0.01 %). Moreover, 
the fatality rate for mixed infection was particularly 
high (0.2 %).
Discussion
Although Colombia has experienced a malaria-decreas-
ing trend during the last decade [1], the observed trend 
for complicated malaria cases reflected a non-significant 
increase during 2007–2013 (APC 14.4  %; 95  % CI −4.3 
to 36.6), with the highest number of cases reported after 
2010 [16]. Notably, between 2007 and 2010 a significant 
rising trend for complicated malaria was found in chil-
dren younger than 5  years of age and women mostly 
infected by P. falciparum. This could be explained by both 
the overall rise on the number of total malaria cases [16] 
and changes in complicated malaria criteria occurred 
in 2010. However, the proportion of total malaria cases 
in women compared to men remained similar during 
the study period. While changes in complicated malaria 
trend could be explained by a higher diagnosis rate due 
to more conservative definitions after 2010, improvement 
in the surveillance system and health care infrastruc-
ture should also be considered. Those data together sug-
gest the need for new public health strategies focused on 
these vulnerable populations.
Complicated malaria represented 0.47  % of 547,542 
malaria cases during 2007–2013, in agreement with a 
previous report of malaria outbreak using SIVIGILA 
information [16]. However, in a passive surveillance con-
ducted between 2011 and 2013 was reported that 45 of 
99 complicated malaria cases were not diagnosed and 
treated as such, but were classified during the laboratory 
data analyses [6], suggesting a possible underreporting of 
complicated malaria cases found here.
Fig. 4 Trend of the API for complicated malaria. The observed (solid 
lines) and modelled (dotted lines) annual parasite incidence (API) for 
100,000 habitants are shown. APC annual percent change
Table 3 Annual percent change (APC) for complicated malaria, stratified by gender
Significant data are highlighted in italics
a A p value <0.05 is interpreted as the trends (slopes) between male and female are significantly different
b A p value <0.05 is interpreted as the rate differences (coincidence of intercepts) between male and female are significantly different
c The 95 % CI of annual percent change (APC) is significantly different of 0 (p < 0.05)
Complicated cases Male Female Comparison between genders
2007 2013 APC % Trend 2007 2013 APC % Trend Test for parallelisma Test for coincidenceb
All parasite species 0.57 1.09 10.5 No change 0.25 0.80 19.9c Rising <0.001 0.006
P. vivax 0.27 0.51 10.4 No change 0.07 0.29 21.9 No change <0.001 <0.001
P. falciparum 0.26 0.53 11.0 No change 0.14 0.44 20.5c Rising 0.113 <0.001
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Although P. falciparum has been classically associated 
with a more severe clinical spectrum, there are multi-
ple studies worldwide reporting an increasing number 
of severe manifestations in P. vivax infections [6, 9, 13, 
17, 25–28], a relevant matter now on the malaria eradi-
cation agenda [29]. In this study, P. vivax was responsi-
ble for 44  % of complicated malaria cases, underscoring 
the importance of P. vivax malaria in a country where it 
causes about 70 % of malaria cases. Although the mecha-
nisms involved in the clinical complications by P. vivax are 
not well understood [30, 31]; recent ex vivo studies have 
shown that P. vivax-infected red blood cells (Pv-iRBC) 
can adhere to endothelial cells [32–34], supporting the 
hypothesis that P. vivax undergoes sequestration in vivo.
Patients with mono-infections by P. falciparum had a 
higher risk of hepatic and neurological manifestations in 
comparison with P. vivax malaria patients. Non-severe 
thrombocytopaenia was found in almost half of com-
plicated malaria cases, similar to a previous report in 
Colombia [6]. That is an important manifestation since 
altered platelet indices have been found as potential 
markers of severe malaria [18, 35]. Unfortunately, further 
information of severe thrombocytopaenia in patients 
studied here was not available.
Table 4 Clinical findings in complicated malaria cases
Most frequent and significant data are highlighted in italics
DIC disseminated intravascular coagulation
a p value using the Chi square test between parasite species
b Non‑severe thrombocytopenia defined as <100,000 platelets/µL
Symptoms/signs P. vivax (n = 1126) P. falciparum  
(n = 1274)
Mixed infection  
(n = 153)
p valuea
n % n % n %
Hyperemesis 127 11.3 193 15.1 17 11.1 0.010
Hepatomegaly 160 14.2 232 18.2 44 28.8 0.001
Splenomegaly 128 11.4 150 11.8 28 18.3 0.045
Clinical jaundice 40 3.6 71 5.6 11 7.2 0.024
Somnolence 121 10.7 195 15.3 28 18.3 0.001
Confusion 44 3.9 85 6.7 14 9.2 0.002
Convulsions 39 3.5 65 5.1 15 9.8 0.010
Coma 14 1.2 6 0.5 0 0 0.180
Thrombocytopaeniab 494 43.9 545 42.8 82 53.6 0.010
Severe anaemia 84 6.9 117 8.3 20 10.9 0.024
Haemorrhage 54 4.8 42 3.3 5 3.3 0.390
DIC 19 1.7 17 1.3 5 3.3 0.190
Haematuria 43 3.8 69 5.4 15 9.8 0.004
Circulatory collapse or shock 31 2.6 12 0.9 6 3.3 0.001
Respiratory distress 56 5.0 62 4.9 10 6.5 0.870
Pulmonary oedema 22 2.0 19 1.5 5 3.3 0.540
Table 5 Frequency of organ-related complications
Total number of complications (according to SIVIGILA notification forms) taking into account that one patient can present more than one complication simultaneously
Most frequent and significant data are highlighted in italics
a p value using the Chi square test
Complication P. vivax P. falciparum Mixed infections Total p valuea
n % n % n % n %
Hepatic 449 37.0 418 29.8 55 30.1 922 33.0 0.002
Renal 313 25.8 487 34.7 56 30.6 856 30.6 <0.001
Pulmonary 183 15.1 138 9.8 17 9.3 338 12.1 <0.001
Cerebral 133 11.0 214 15.3 24 13.1 371 13.3 0.002
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Although severe anaemia was rather uncommon in 
mono-infections (~8 %), as also shown by other Colom-
bian studies [6, 8, 10–13], renal and cerebral complica-
tions were significantly more common in patients with 
P. falciparum infections. In contrast, in patients with P. 
vivax, cerebral complications were less frequent (11  %), 
while hepatic and pulmonary complications were more 
common than in P. falciparum patients. The presence 
of other possible central nervous system pathogens 
has not been ruled out in this and other studies report-
ing malaria cerebral complications as reviewed in [28]. 
Indeed, it has been suggested that comma in P. vivax is 23 
times less common than in P. falciparum infections [28]. 
The high number of cases with cerebral complications 
reported in this study contrasts significantly with previ-
ous reports from Colombia, with 1/92 complicated cases 
by P. falciparum [11], no cerebral malaria cases in 16 P. 
vivax complicated patients [13], and only one case of P. 
vivax cerebral malaria complicated with venous sinus 
thrombosis reported recently [36]. The contrasting high 
number of cerebral malaria cases reported to SIVIGILA, 
suggests an inappropriate classification probably due to 
errors during the filling or typing form process.
In contrast with mono-infected patients, complicated 
malaria was more frequent in patients with mixed infec-
tions, which presented commonly with hepatic and neu-
rological manifestations, as well as severe anaemia and 
shock complications. Moreover, a high fatality rate was 
observed in those patients. Although some studies have 
suggested that P. vivax appears to attenuate the severity 
of the P. falciparum infection [37–39], others suggest that 
mixed infections could be associated with more severe 
disease, leading to a higher risk for severe anaemia, mul-
tiple organ dysfunction and mortality [12, 38, 40].
In agreement with other studies, a higher number of 
complicated malaria cases was found in young males [6, 
16, 25, 28]; which could be explained by occupational 
factors such as mining, timber or farming that increase 
the risk of malaria infection. Notably, a diagnosis delay 
(>72 h after symptoms onset) was found in most patients, 
possibly due to either limited access to healthcare ser-
vices (less developed on the Pacific Coast) or health staff 
failure to identify complicated malaria manifestations. 
Moreover, this delayed diagnosis increases the risk of 
anaemia [41]. Although a re-infection or relapse cannot 
be ruled out in patients reporting previous malaria epi-
sodes in the last month, which was significantly more 
common in cases with mixed infection, it suggests ther-
apeutic failure or low adherence to anti-malarial treat-
ment. Both delayed and the limited availability of the first 
line of anti-malarial drugs at health institutions could be 
responsible for higher parasite burden and secondary 
severe malaria.
These findings demonstrate the Colombian Health Sys-
tem faults in prompt recognition of complicated malaria 
patients as well as the difficulties around appropriate 
treatment provision; which may explain why the API for 
complicated malaria remained almost stable while API 
for total malaria cases decreased over the years. Although 
the databases were refined according to the national sys-
tem, some data including demographic, epidemiologi-
cal and clinical information were missed in less than 2 % 
of cases. Other constraints such as errors during the 
malaria notification form filling or typing process can-
not be ruled out. Also, there may be misclassification of 
cases resulting from lack of adherence to case definitions, 
errors in species diagnosis -since molecular confirmation 
was not performed- and missing information about co-
morbidities or co-infections. Although the Colombian 
guidelines use the same criteria to define complicated 
vivax and falciparum malaria [21], similar to the estab-
lished by the WHO in 2014 [42]; the criterion of hyper-
parasitaemia must be re-evaluated in the Colombian 
guidelines since P. vivax invades reticulocytes and their 
parasite densities are usually lower than P. falciparum. 
Moreover, because the co-morbidities may modify the 
malaria episode course, this must be also included in the 
notification forms. Currently, the MoH is doing efforts 
in the reinforcement of health personnel knowledge and 
training about malaria disease and the correct notifica-
tion process, especially in endemic areas with limited 
health infrastructure to strength the malaria information 
system in Colombia.
It is important to highlight that since the information 
reported here was obtained from the SIVIGILA, the data 
contained in the notification forms are the required for 
malaria surveillance and not for the clinical characteri-
zation. Thus, in this study malaria complications were 
presented as organ-related complications grouped in 
four categories (cerebral, pulmonary, hepatic, and renal 
complications) as appear in the SIVIGILA malaria case 
notification forms, instead of clinical and/or laboratory 
criteria of complications, as it is suggested by national 
and international guidelines. This categorization excludes 
several of the defined clinical and laboratory parameters 
but includes others in the notification forms under the 
clinical findings section. Therefore, parameters such as 
shock, haematological alterations, metabolic acidosis, 
haemoglobinuria, and hyperparasitaemia, which did not 
completely fit any of the four categories of complications, 
were excluded from the surveillance; suggesting consid-
erable underreporting of total complicated malaria cases. 
Nevertheless, SIVIGILA malaria case notification forms 
were modified in 2016, reclassifying complications in six 
groups: cerebral, renal, hepatic, pulmonary, haemato-
logical, and other complication. Prospective studies that 
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evaluate parasite (virulence, genetic profile, anti-malarial 
drug resistance) and host susceptibility factors (co-mor-
bidities, co-infections, age of exposure, immunological 
and nutritional status) in conjunction with clinical and 
laboratory profile of complicated malaria patients should 
be conducted to improve existing knowledge of the clini-
cal presentation spectrum and risks.
Conclusion
During the last decade, Colombia presented a significant 
decrease in malaria clinical cases and associated mortal-
ity. However, it appears that the prevalence of compli-
cated malaria remained stable. Despite existing national 
policies on early diagnosis and prompt anti-malarial 
treatment to prevent complicated malaria cases, more 
efforts have to be committed to decrease the total num-
ber of malaria cases, including the complicated ones. 
These efforts should include taking action to improve the 
malaria notification forms, medical assistance skills and 
capacity as well as to increase the knowledge of malaria-
related risk factors, morbidity and mortality.
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